
Across 26 years at Lilly and seven as Neurocrine's chief medical officer, Eiry Roberts learned that drug development is less a straight line than a chain of judgment calls. Her next chapter puts that operating memory to work in the boardroom.
One movement-disorder medicine turned a San Diego research shop into a multibillion-dollar biopharma. Now Neurocrine is spending that advantage on rare endocrine disease, psychiatry and the difficult biology between brain and body.